市場調査レポート

商品コード

1382559

眼科局所治療薬の世界市場の予測（～2030年）

Ophthalmic Topical Therapeutics Market Forecast till 2030

出版日: 2023年11月15日
発行: Market Research Future
ページ情報: 英文 148 Pages
納期: 即納可能

価格

PDF & Excel (Single User License)

USD 4,950 726,759円

レポートPDF、Excelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。

PDF & Excel (Multi User License)

USD 5,950 873,579円

レポートPDF、Excelを同一企業内の最大15名がご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。

PDF & Excel (Enterprise License)

USD 7,250 1,064,445円

レポートPDF、Excelを同一企業内のすべての方がご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDF、Excelの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の眼科局所治療薬の市場規模は、予測期間（2023年～2030年）にCAGRで7.25%の大幅な成長が予測されています。

市場は老年人口の増加や眼科疾患の拡大によって牽引されています。屈折異常、ドライアイ、緑内障、視覚過敏、加齢黄斑変性症などの眼科疾患が世界中で増加しており、市場成長を促進しています。

地域の考察

北米市場が2022年にもっとも大きなシェアを占めました。主な変数は、眼病患者の増加、老年人口の増加、同地域における膨大な数の市場企業のプレゼンスです。

欧州市場が2番目に大きなシェアを占めています。その理由は、先進国における老年人口の拡大、医療サービスのグローバリゼーション、糖尿病やその他の合併症の増加です。

アジア太平洋市場は2023年～2030年にもっとも急速な市場成長が見込まれています。これは眼科疾患の負担の増大や、購入者の意識の向上、最先端の技術革新の採用の拡大によるものです。各組織は、患者に新たな治療の選択肢を生み出し普及させるため、重要な活動を行っています。

当レポートでは、世界の眼科局所治療薬市場について調査分析し、市場力学、地域とセグメントの分析、企業プロファイルなどを提供しています。

バリューチェーン分析
- 研究開発
- 製造
- 流通・販売
- 販売後モニタリング
ポーターのファイブフォース分析モデル
COVID-19の眼科局所治療薬市場に対する影響
- サプライチェーンに対する影響
- 生産に対する影響
- 市場参入企業に対する影響

第6章世界の眼科局所治療薬市場：製品タイプ別

概要
人工涙液
抗アレルギー
抗生点眼薬
抗炎症
抗緑内障
その他

第7章世界の眼科局所治療薬市場：疾患別

概要
ドライアイ
目のアレルギー
緑内障
眼感染症
網膜疾患
ブドウ膜炎
その他

第8章世界の眼科局所治療薬市場：剤形別

概要
目薬
ジェル
軟膏
その他

第9章世界の眼科局所治療薬市場：流通チャネル別

概要
病院の薬局
ドラッグストア
オンライン薬局
その他

第10章世界の眼科局所治療薬市場：地域別

概要
北米
- 米国
- カナダ
欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋
その他の地域
- 中東
- アフリカ
- ラテンアメリカ

第11章競合情勢

概要
競合ベンチマーキング
世界の眼科局所治療薬市場における主な成長戦略
世界の眼科局所治療薬市場における開発数の主要企業
主な開発の分析
主な発展と成長戦略
- 製品の承認と製品の発売/パイプライン薬品
- パートナーシップ/提携
- 事業拡大/契約
- 合併・買収
主要企業の売上の分析
- 売上・営業利益
主要企業の研究開発の分析

第12章企業プロファイル

SANTEN PHARMACEUTICAL CO., LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD
NOVARTIS AG
ABBVIE INC.
BAUSCH & LOMB INCORPORATED
AMNEAL PHARMACEUTICALS LLC.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
ALCON
VIATRIS INC.

第13章付録

図表

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 4 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ARTIFICIAL TEARS, BY REGION, 2019-2030 (USD BILLION)
TABLE 5 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTI-ALLERGY, BY REGION, 2019-2030 (USD BILLION)
TABLE 6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTIBIOTIC DROPS, BY REGION, 2019-2030 (USD BILLION)
TABLE 7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTI-INFLAMMATORY, BY REGION, 2019-2030 (USD BILLION)
TABLE 8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTIGLAUCOMA, BY REGION, 2019-2030 (USD BILLION)
TABLE 9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 11 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR DRY EYE, BY REGION, 2019-2030 (USD BILLION)
TABLE 12 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE ALLERGY, BY REGION, 2019-2030 (USD BILLION)
TABLE 13 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR GLAUCOMA, BY REGION, 2019-2030 (USD BILLION)
TABLE 14 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE INFECTION, BY REGION, 2019-2030 (USD BILLION)
TABLE 15 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR RETINAL DISORDERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 16 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR UVEITIS, BY REGION, 2019-2030 (USD BILLION)
TABLE 17 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 18 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 19 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE DROPS, BY REGION, 2019-2030 (USD BILLION)
TABLE 20 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR GELS, BY REGION, 2019-2030 (USD BILLION)
TABLE 21 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OINTMENTS, BY REGION, 22019-2030 (USD BILLION)
TABLE 22 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 23 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 24 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019-2030 (USD BILLION)
TABLE 25 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR DRUG STORES, BY REGION, 2019-2030 (USD BILLION)
TABLE 26 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019-2030 (USD BILLION)
TABLE 27 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 28 GLOBAL: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION, 2019-2030 (USD BILLION)
TABLE 29 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
TABLE 30 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 31 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 32 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 33 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 34 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 35 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 36 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 37 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 38 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 39 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 40 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 41 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 42 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
TABLE 43 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 44 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 45 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 46 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 47 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 48 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 49 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 50 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 51 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 52 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 53 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 54 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 55 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 56 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 57 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 58 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 59 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 60 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 61 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 62 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 63 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 64 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 65 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 66 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 67 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 68 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 69 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 70 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 71 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
TABLE 72 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 73 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 74 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 75 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 76 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 77 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 78 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 79 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 80 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 81 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 82 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 83 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 84 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 85 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 86 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 87 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 88 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 89 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 90 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 91 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
TABLE 92 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030 (USD BILLION)
TABLE 93 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 94 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 95 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
TABLE 96 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 97 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 98 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 99 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
TABLE 100 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY 2019-2030(USD BILLION)
TABLE 101 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030(USD BILLION)
TABLE 102 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030(USD BILLION)
TABLE 103 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
TABLE 104 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
TABLE 105 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
TABLE 106 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030 (USD BILLION)
TABLE 107 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
TABLE 108 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
TABLE 109 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
TABLE 110 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030(USD BILLION)
TABLE 111 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
TABLE 112 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030 (USD BILLION)
TABLE 113 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
TABLE 114 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030 (USD BILLION)
TABLE 115 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030 (USD BILLION)
TABLE 116 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
TABLE 117 MAJOR MANUFACTURERS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
TABLE 118 MOST ACTIVE PLAYER IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
TABLE 119 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS
TABLE 120 PARTNERSHIP/COLLABORATION
TABLE 121 BUSINESS EXPANSIONS/ AGREEMENTS
TABLE 122 MERGERS & ACQUISITIONS
TABLE 123 SANTEN PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED
TABLE 124 SANTEN PHARMACEUTICAL CO., LTD.: KEY DEVELOPMENTS
TABLE 125 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED
TABLE 126 GENENTECH, INC.: KEY DEVELOPMENTS
TABLE 127 NOVARTIS AG: PRODUCTS OFFERED
TABLE 128 NOVARTIS AG.: KEY DEVELOPMENTS
TABLE 129 ABBVIE INC.: PRODUCTS OFFERED
TABLE 130 ABBVIE INC.: KEY DEVELOPMENTS
TABLE 131 BAUSCH & LOMB INCORPORATED: PRODUCTS OFFERED
TABLE 132 BAUSCH & LOMB INCORPORATED: KEY DEVELOPMENTS
TABLE 133 AMNEAL PHARMACEUTICALS LLC.: PRODUCTS OFFERED
TABLE 134 AMNEAL PHARMACEUTICALS., LLC.: KEY DEVELOPMENTS
TABLE 135 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 136 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 137 ALCON: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 138 ALCON: KEY DEVELOPMENTS
TABLE 139 AKORN OPERATING COMPANY LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 140 VIATRIS INC.: PRODUCTS/SERVICES OFFERED
TABLE 141 VIATRIS INC.: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: OPHTHALMIC TOPICAL THERAPEUTICS MARKET
FIGURE 5 DRIVERS: IMPACT ANALYSIS
FIGURE 6 RESTRAINT: IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
FIGURE 9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2022 & 2030 (USD BILLION)
FIGURE 10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY PRODUCT TYPE, 2022
FIGURE 11 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2022 & 2030 (USD BILLION)
FIGURE 12 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY DISEASE TYPE, 2022
FIGURE 13 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2022 & 2030 (USD BILLION)
FIGURE 14 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY DOSAGE FORM, 2022
FIGURE 15 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2030 (USD BILLION)
FIGURE 16 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2021
FIGURE 17 GLOBAL: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION 2022 & 2030 (USD BILLION)
FIGURE 18 GLOBAL: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY REGION 2022
FIGURE 19 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 20 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 21 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 22 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 23 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 24 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
FIGURE 25 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET: COMPETITIVE LANDSCAPE
FIGURE 26 MAJOR PLAYERS SALES & OPERATING INCOME, 2022 (USD BILLION)
FIGURE 27 MAJOR PLAYERS R&D EXPENDITURE, 2022 (USD BILLION)
FIGURE 28 SANTEN PHARMACEUTICAL CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 NOVARTIS AG.: SWOT ANALYSIS
FIGURE 32 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 ABBVIE INC.: SWOT ANALYSIS
FIGURE 34 BAUSCH & LOMB INCORPORATED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 BAUSCH & LOMB INCORPORATED: SWOT ANALYSIS
FIGURE 36 AMNEAL PHARMACEUTICALS LLC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 39 ALCON: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 ALCON: SWOT ANALYSIS
FIGURE 41 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT

Product Code: MRFR/HC/10564-HCR

Market Overview

The Ophthalmic Topical Therapeutics is estimated to register a significant CAGR of 7.25% during the forecast period (2023 - 2030).

This market is being driven by a few elements, remembering an ascent for geriatric populace and expanding pervasiveness of ophthalmic problems.

There is a rising commonness of ophthalmic problems like refractive blunders, dry eye, glaucoma, eye sensitivities, and age-related macular degeneration internationally which is driving the market development. As per the WHO in October 2021, somewhere around 2.2 billion individuals universally experience the ill effects of vision weakness. The main sources of vision hindrance are refractive blunders and waterfall, the two of which have topical ophthalmic restorative items accessible on the lookout. Essentially, glaucoma is a main source of irreversible visual impairment universally. As indicated by Public Glaucoma Exploration, north of 3 million Americans have glaucoma. As per the WHO in 2021, over 7.7 million individuals experience the ill effects of glaucoma worldwide. The most widely recognized treatment for glaucoma is remedy eye drops like beta-blockers, prostaglandins, Rho-kinase inhibitors, and others that can hold glaucoma back from deteriorating.

Market Segmentation

The Market fragments of Ophthalmic Topical Therapeutics, based on type, incorporates fake tears, against sensitivity, anti-toxin drops, mitigating, antiglaucoma, and others. The Market division, in view of disease type, incorporates dry eye, eye sensitivity, glaucoma, eye disease, retinal issues, uveitis, and others. In view of dose form, the worldwide ophthalmic topical therapeutics industry is divided into eye drops, gels, salves, and others.

The Market division of Ophthalmic Topical Therapeutics, in view of distribution channel, incorporates clinic drug stores, pharmacies, online drug stores, and others.

Regional Insights

The North America ophthalmic topical therapeutics market represented the biggest piece of the pie in 2022. Key variables credited to its rising commonness of eye sickness, rising geriatric populace, and the presence of an enormous number of market players in the district. Moreover, the rising commonness of ophthalmic illnesses is driving the market interest for ophthalmic topical therapeutics in North America. Factors like an expansion in the geriatric populace, progressions in innovative work in optometry, and the expansion in the utilization of ophthalmic medications in emergency clinic drug stores are supposed to expand the interest for ophthalmic topical therapeutics in the US.

Europe ophthalmic topical therapeutics market represented the second-biggest piece of the pie because of expanding geriatric populace in the created nations, globalization of medical services, and rising weight of diabetes and other comorbidities.

The Asia-Pacific ophthalmic topical therapeutics market is supposed to be the quickest developing from 2023 to 2030 because of the rising expanding weight of ophthalmic problems and rising buyer mindfulness, and the developing reception of cutting-edge innovations. Organizations are going into key drives to create and popularize new treatment choices for patients.

Major Players

Key Companies in the market of ophthalmic topical therapeutics includes Santen pharmaceutical co., Ltd. (Japan), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), AbbVie (US), Bausch & Lomb Incorporated (US), Amneal Pharmaceuticals., LLC (US), Teva Pharmaceutical Industries Ltd. (Israel), Alcon (Switzerland), Akorn Operating Company LLC (US), and Viatris Inc. (US).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 RISE IN GERIATRIC POPULATION
- 4.2.2 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS
4.3 RESTRAINTS
- 4.3.1 LACK OF AWARENESS REGARDING EYE DISORDERS
4.4 OPPORTUNITIES
- 4.4.1 GROWING NUMBER OF TOPICAL DRUGS IN THE PIPELINE

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE OPHTHALMIC TOPICAL THERAPEUTICS MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON PRODUCTTION
- 5.3.3 IMPACT ON MARKET PLAYERS

6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE

6.1 OVERVIEW
6.2 ARTIFICIAL TEARS
6.3 ANTI-ALLERGY
6.4 ANTIBIOTIC DROPS
6.5 ANTI-INFLAMMATORY
6.6 ANTIGLAUCOMA
6.7 OTHERS

7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE

7.1 OVERVIEW
7.2 DRY EYE
7.3 EYE ALLERGY
7.4 GLAUCOMA
7.5 EYE INFECTION
7.6 RETINAL DISORDERS
7.7 UVEITIS
7.8 OTHERS

8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM

8.1 OVERVIEW
8.2 EYE DROPS
8.3 GELS
8.4 OINTMENTS
8.5 OTHERS

9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 DRUG STORES
9.4 ONLINE PHARMACIES
9.5 OTHERS

10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 UK
- 10.3.3 FRANCE
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
- 10.4.1 JAPAN
- 10.4.2 CHINA
- 10.4.3 INDIA
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS
- 11.6.2 PARTNERSHIP/COLLABORATION
- 11.6.3 BUSINESS EXPANSIONS/AGREEMENTS
- 11.6.4 MERGERS & ACQUISITIONS
11.7 MAJOR PLAYERS SALES ANALYSIS
- 11.7.1 SALES & OPERATING INCOME
11.8 MAJOR PLAYERS R&D ANALYSIS

12 COMPANY PROFILES

12.1 SANTEN PHARMACEUTICAL CO., LTD.
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS/SERVICES OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 KEY STRATEGIES
12.2 SUN PHARMACEUTICAL INDUSTRIES LTD
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS/SERVICES OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 KEY STRATEGIES
12.3 NOVARTIS AG
- 12.3.1 COMPANY OVERVIEWS
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS/SERVICES OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 ABBVIE INC.
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
12.5 BAUSCH & LOMB INCORPORATED
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
12.6 AMNEAL PHARMACEUTICALS LLC.
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS/SERVICES OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 KEY STRATEGIES
12.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL ANALYSIS
- 12.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
12.8 ALCON
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS/SERVICES/SOLUTIONS 0FFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 AKORN OPERATING COMPANY LLC
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 VIATRIS INC.
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS/SERVICES OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

13 APPENDIX

13.1 REFERENCES
13.2 RELATED REPORTS

眼科局所治療薬の世界市場の予測（～2030年）

Ophthalmic Topical Therapeutics Market Forecast till 2030

目次

第1章エグゼクティブサマリー

第2章市場のイントロダクション

第3章調査手法

第4章市場力学

第5章市場要因の分析

第6章世界の眼科局所治療薬市場：製品タイプ別

第7章世界の眼科局所治療薬市場：疾患別

第8章世界の眼科局所治療薬市場：剤形別

第9章世界の眼科局所治療薬市場：流通チャネル別

第10章世界の眼科局所治療薬市場：地域別

第11章競合情勢

第12章企業プロファイル

第13章付録

LIST OF TABLES

LIST OF FIGURES

Market Overview

Market Segmentation

Major Players

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

3 RESEARCH METHODOLOGY

4 MARKET DYNAMICS

5 MARKET FACTOR ANALYSIS

6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE

7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE

8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM

9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION

11 COMPETITIVE LANDSCAPE

12 COMPANY PROFILES

13 APPENDIX

眼科局所治療薬の世界市場の予測（～2030年）

Ophthalmic Topical Therapeutics Market Forecast till 2030

目次

第1章 エグゼクティブサマリー

第2章 市場のイントロダクション

第3章 調査手法

第4章 市場力学

第5章 市場要因の分析

第6章 世界の眼科局所治療薬市場：製品タイプ別

第7章 世界の眼科局所治療薬市場：疾患別

第8章 世界の眼科局所治療薬市場：剤形別

第9章 世界の眼科局所治療薬市場：流通チャネル別

第10章 世界の眼科局所治療薬市場：地域別

第11章 競合情勢

第12章 企業プロファイル

第13章 付録

LIST OF TABLES

LIST OF FIGURES

Market Overview

Market Segmentation

Major Players

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

3 RESEARCH METHODOLOGY

4 MARKET DYNAMICS

5 MARKET FACTOR ANALYSIS

6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE

7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE

8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM

9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION

11 COMPETITIVE LANDSCAPE

12 COMPANY PROFILES

13 APPENDIX

第1章エグゼクティブサマリー

第2章市場のイントロダクション

第3章調査手法

第4章市場力学

第5章市場要因の分析

第6章世界の眼科局所治療薬市場：製品タイプ別

第7章世界の眼科局所治療薬市場：疾患別

第8章世界の眼科局所治療薬市場：剤形別

第9章世界の眼科局所治療薬市場：流通チャネル別

第10章世界の眼科局所治療薬市場：地域別

第11章競合情勢

第12章企業プロファイル

第13章付録